NCT01152788 - Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 5, 2010

Primary Completion Date

November 25, 2014

Study Completion Date

February 13, 2015

Conditions

Melanoma

Interventions

DRUG

rIL-21

30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks

DRUG

Dacarbazine

1000 mg/m2 IV Day 1, every 3 weeks

Trial Locations (19)

90025

The Angeles Clinic and Research Institute, Los Angeles

T2N 4N2

Tom Baker Cancer Centre, Calgary

V3V 1Z2

BCCA - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

V8R 6V5

BCCA - Vancouver Island Cancer Centre, Victoria

R3E 0V9

CancerCare Manitoba, Winnipeg

E2L 4L2

Atlantic Health Sciences Corporation, Saint John

B3H 1V7

QEII Health Sciences Center, Halifax

P3E 5J1

Northeast Cancer Center Health Sciences, Greater Sudbury

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Health Research Institute - General Division, Ottawa

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

J4V 2H1

Hopital Charles LeMoyne, Greenfield Park

H2L 4M1

CHUM - Hopital Notre-Dame, Montreal

H2W 1S6

McGill University - Dept. Oncology, Montreal

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon